{"entity":{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","aka":["Primary vaginal squamous cell carcinoma","HPV-related vaginal cancer","Vaginal cancer treated with chemoradiotherapy","VAIN and vaginal squamous carcinoma"],"tldr":"Vaginal squamous cell carcinoma is the commonest form of vaginal cancer, caused by the same HPV infection as cervical cancer and often following earlier cervical disease. It is treated much as cervical cancer is, with radiotherapy, brachytherapy and cisplatin for most stages and surgery only for small upper-vaginal tumours, and it is prevented by HPV vaccination and cervical screening.","summary":"Squamous cell carcinoma makes up most primary vaginal cancers and shares its cause and precursor with cervical cancer: persistent high-risk HPV infection leading to vaginal intraepithelial neoplasia (VAIN), which is commonest at the vaginal vault after hysterectomy for cervical precancer. The strict definition excludes tumours that reach the cervix or vulva, which are classified as cervical or vulvar, and metastases from the cervix, endometrium and bowel outnumber true primaries. Diagnosis is by biopsy at colposcopy, staging is clinical and by MRI and PET-CT under the FIGO system shared with cervical cancer, and p16 confirms HPV association.\n\nBecause the disease is rare, no randomised trial has ever been run in it, and treatment is extrapolated from cervical cancer. High-grade VAIN is treated with laser ablation, excision, topical imiquimod or fluorouracil, or brachytherapy for extensive vault disease. Small stage I tumours of the upper vagina can be removed by radical upper vaginectomy with pelvic lymphadenectomy, but most patients receive external beam radiotherapy to the pelvis and groins followed by brachytherapy, with concurrent weekly cisplatin for stage II and above by analogy with cervical chemoradiotherapy; brachytherapy dose is the strongest determinant of local control. Recurrent or metastatic disease is treated as cervical cancer, with carboplatin and paclitaxel with or without bevacizumab and with pembrolizumab for PD-L1-positive tumours, extrapolating KEYNOTE-826. HPV vaccination and cervical screening prevent the disease, and Chinese vaccine trials list vaginal cancer among their endpoints.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Vaginal_cancer","links":[{"label":"NCCN Vaginal Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Vaginal_cancer"}],"tags":["subtype-page","gynaecologic"],"related":["vaginal-adenocarcinoma","vaginal","locally-advanced-cervical-cancer","hpv-associated-vulvar-cancer"],"cancers":[],"sections":[],"technologies":["brachytherapy","imrt-igrt","checkpoint-inhibitor","hpv-vaccine","hpv-testing","colposcopy-excision","precancer-ablation"],"targets":["pd1","pdl1"],"drugs":["cisplatin","carboplatin","paclitaxel","pembrolizumab","fluorouracil","gardasil-9"],"companies":[],"institutions":[],"pathways":[],"terms":["hpv-p16","hpv-status","chemoradiation","cin-hsil","lymphadenectomy"],"trials":["nct04422366","nct05027776","nct07572396","keynote-826"],"people":[],"bottlenecks":[],"keyPapers":["paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018","paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006"],"journals":[],"dependsOn":[],"notes":[],"group":"gynaecologic","burden":"The large majority of primary vaginal cancers, mostly in women over 60, many with a history of cervical precancer or hysterectomy for it; a tumour is called vaginal only when the cervix and vulva are uninvolved.","subtypes":["High-grade vaginal intraepithelial neoplasia (VAIN 2 to 3, precursor, often at the vault after hysterectomy)","Stage I vaginal squamous cell carcinoma (upper vagina, surgery or brachytherapy)","Stage II to IVA vaginal squamous cell carcinoma (chemoradiotherapy with brachytherapy)","HPV-associated vaginal cancer after cervical precancer","Recurrent or metastatic vaginal squamous cell carcinoma (treated as cervical cancer)"],"biomarkers":["HPV DNA and p16 immunohistochemistry","FIGO stage (clinical, MRI, PET-CT)","Prior cervical neoplasia or hysterectomy","PD-L1 combined positive score (pembrolizumab, extrapolated)","Brachytherapy dose delivered (local control)"],"standardOfCare":[{"setting":"Precursor (VAIN)","approach":"Laser ablation or excision; topical imiquimod or fluorouracil; brachytherapy for extensive vault disease; HPV vaccination and screening for prevention.","refs":["colposcopy-excision","precancer-ablation","fluorouracil","brachytherapy","hpv-vaccine","gardasil-9","nct04422366","nct05027776"],"guideline":{"version":"NCCN Guidelines: Vaginal Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481"}},{"setting":"Stage I, upper vagina","approach":"Radical upper vaginectomy with pelvic lymphadenectomy, or brachytherapy with or without external beam radiotherapy.","refs":["brachytherapy","lymphadenectomy"],"guideline":{"version":"NCCN Guidelines: Vaginal Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481"}},{"setting":"Stage II to IVA","approach":"External beam radiotherapy to the pelvis (and groins for lower-third tumours) with concurrent weekly cisplatin, followed by brachytherapy, extrapolating from cervical cancer.","refs":["imrt-igrt","brachytherapy","cisplatin","chemoradiation"],"guideline":{"version":"NCCN Guidelines: Vaginal Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481"}},{"setting":"Recurrent or metastatic disease","approach":"Carboplatin and paclitaxel with or without bevacizumab; pembrolizumab for PD-L1-positive tumours (KEYNOTE-826 extrapolated); pelvic exenteration for isolated central recurrence after radiotherapy.","refs":["carboplatin","paclitaxel","pembrolizumab","keynote-826"],"guideline":{"version":"NCCN Guidelines: Vaginal Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481"}}],"stateOfArt":["Image-guided brachytherapy gives high local control in stage I and II disease.","Chemoradiotherapy is standard for stage II and above by extrapolation from cervical cancer.","HPV vaccination and cervical screening are preventing the disease in younger cohorts."],"history":[{"year":1933,"title":"Vaginal intraepithelial neoplasia first described","refs":[]},{"year":1999,"title":"Cisplatin chemoradiotherapy becomes standard in cervical cancer and is adopted for vaginal cancer","refs":["cisplatin","chemoradiation"]},{"year":2006,"title":"HPV vaccine approved with protection against vaginal precancer","refs":["hpv-vaccine","gardasil-9"]},{"year":2021,"title":"KEYNOTE-826 adds pembrolizumab to first-line therapy in cervical cancer, extrapolated to vaginal cancer","refs":["pembrolizumab","keynote-826"]}],"pipeline":["pembrolizumab","hpv-vaccine","nct07572396"],"openProblems":["No randomised trial has ever been conducted in vaginal cancer.","Radiotherapy causes vaginal stenosis and sexual morbidity that are poorly addressed.","The role of chemotherapy with radiotherapy is assumed, not proven.","Tumours at the vault after hysterectomy are hard to distinguish from recurrent cervical cancer."],"parent":"vaginal"},"route":"/cancers/vaginal-squamous-cell-carcinoma/","neighbours":{"cancer":[{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/"},{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/"},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/"}],"technology":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"},{"id":"colposcopy-excision","kind":"technology","name":"Colposcopy and excisional treatment (LEEP/LLETZ, cone)","route":"/technologies/colposcopy-excision/"},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"},{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"cin-hsil","kind":"term","name":"Cervical precancer (CIN, HSIL/LSIL)","route":"/terms/cin-hsil/"},{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"},{"id":"hpv-status","kind":"term","name":"HPV status (HPV-positive / HPV-negative)","route":"/terms/hpv-status/"},{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/"},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/"}],"trial":[{"id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","route":"/trials/nct04422366/"},{"id":"nct05027776","kind":"trial","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","route":"/trials/nct05027776/"},{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/"},{"id":"nct07572396","kind":"trial","name":"Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","route":"/trials/nct07572396/"}],"paper":[{"id":"paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006","kind":"paper","name":"Carcinoma of the vagina: FIGO 26th Annual Report on the results of treatment in gynecological cancer","route":"/key-papers/paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006/"},{"id":"paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018","kind":"paper","name":"FIGO Cancer Report 2018: cancer of the vagina","route":"/key-papers/paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018/"}]}}